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The phosphatidylinositol (PI) hydrolysis signaling system has been shown to be altered in platelets of depressed and schizophrenic
subjects. Inositol (1,4,5) trisphosphate (Ins(1,4,5)P3), an integral component of the PI signaling system, mobilizes Ca
2+ by
activating Ins(1,4,5)P3 receptors. To eventually investigate the role of Ins(1,4,5)P3 receptors in depression and other mental
disorders, we characterized [3H]Ins(1,4,5)P3 binding sites in crude platelet membranes prepared from small amounts of
blood obtained from healthy human control subjects. We found a single, saturable binding site for [3H]Ins(1,4,5)P3 to crude
platelet membranes, which is time dependent and modulated by pH, inositol phosphates, and heparin. Since cyclic adenosine
monophosphate (cAMP) and Ca
2+ have been shown to be important modulators in Ins(1,4,5)P3 receptors, in the present study we
also determined the eﬀects of various concentrations of CaCI2 and forskolin on Ins(1,4,5)P3 binding to platelet membranes. CaCI2
modulated [3H]Ins(1,4,5)P3 binding sites in a biphasic manner: at lower concentrations it inhibited [3H]Ins(1,4,5)P3 binding,
whereas at higher concentrations, it stimulated [3H]Ins(1,4,5)P3 binding. On the other hand, forskolin inhibited [3H]Ins(1,4,5)P3
binding.Ourresultsthussuggestthatthepharmacologicalcharacteristicsof[3H]Ins(1,4,5)P3 bindingtocrudeplateletmembranes
are similar to that of Ins(1,4,5)P3 receptors; and that both Ca
2+ and cAMP modulate [3H]Ins(1,4,5)P3 binding in crude platelet
membranes.
Copyright © 2009 Y. Dwivedi and G. N. Pandey. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Agonist-stimulated activation of cell surface receptors, such
as 5HT2A,5 H T 2C, α adrenergic, and muscarinic recep-
tors, leads to the hydrolysis of phosphatidylinositol 4,5-
bisphosphate by stimulating phospholipase C (PLC) and
subsequently generating two second messengers: diacylglyc-
erol (DG) and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3).
DG activates protein kinase C (PKC) [1], while Ins(1,4,5) P3
triggers the release of Ca2+ from intracellular sources by
interacting with Ins(1,4,5)P3 receptors [2–4]. Ins(1,4,5)P3
receptors have been identiﬁed and characterized in both
central and peripheral tissues, such as the brain [5], the
hepatic plasma membranes [6], smooth muscle cells [7,
8], rat cerebral and bovine adrenocortical membranes [9],
and the rat cerebellum [10]. Cloning studies in various
tissues show the existence of three types (I, II, and III) of
Ins(1,4,5)P3 receptors [11–13] .A l la r eb e l i e v e dt oa c ta sC a 2+
channels [4, 14].
Similar to other cell types, Ins(1,4,5)P3 in platelets also
functions as a second messenger and mobilizes calcium
(Ca2+) by activating the Ins(1,4,5)P3 receptor site [15,
16], which plays an important role in platelet responses
involved in homeostasis and thrombosis. Platelets oﬀer a
suitable peripheral model for studying abnormalities in
neurotransmitter receptors and receptor-mediated second
messenger systems such as adenylyl cyclase-cyclic adenosine
monophosphate (cAMP) and the phosphatidyl inositol (PI)
hydrolysis signaling system. Some reports indicate that the
PI signaling system is altered in the platelets of depressed and
schizophrenic subjects. Kaiya et al. [17] showed an increase
inDGintheplateletsofschizophrenicsubjectsandproposed
that this increase may cause a decrease in Ins(1,4,5)P3/Ca2+
function. Also Mikuni et al. [18] reported an increase in
5HT-induced accumulation of inositol phosphate-1 (IP1)
in the platelets of depressed patients compared to control
subjects. We also observed that thrombin-stimulated IP1
receptors formation was signiﬁcantly greater in depressed2 Cardiovascular Psychiatry and Neurology
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Figure 1: The eﬀect of pH on [3H]Ins(1,4,5)P3 binding to human
platelet membranes. Binding at diﬀerent pH values was performed
as described in Section 2. The reaction mixture contained 20nM
[3H]Ins(1,4,5)P3 and approximately 100μg protein. Nonspeciﬁc
binding was determined in the presence of 10μM D-Ins(1,4,5)P3.
Incubations were carried out at 4◦C for 10minutes. Each point
represents the mean value of two experiments performed in
duplicate.
patients compared to control subjects [19]. Since the above-
mentioned studies indicate abnormalities in the PI signal-
ing system in depression, it is quite possible that these
abnormalities may also be associated with alterations in
Ins(1,4,5)P3 receptors. Therefore, it is important to examine
Ins(1,4,5)P3 receptorsintheplateletsofthesesubjects.Sofar,
the role of Ins(1,4,5)P3 receptors in platelets of patients with
mentaldisordershasnotbeenstudied.Toeventuallyexamine
if Ins(1,4,5)P3 receptors are altered in depressed subjects
and patients with other mental disorders, we characterized
Ins(1,4,5)P3 receptors in crude platelet membranes obtained
from normal human control subjects. Although Ins(1,4,5)P3
receptors have been characterized in puriﬁed intracellular
human platelet membranes rich in dense tubular systems
[20], for clinical studies it is important to examine if
Ins(1,4,5)P3 receptors can be studied in crude membranes
since it is not feasible to obtain large amounts of blood from
patient populations.
Ca2+ and cAMP are two potent modulators in
Ins(1,4,5)P3 receptors in various tissues (5,21,22,23).
Depending on its concentration, Ca2+ has been shown to
alter [3H]Ins(1,4,5)P3 binding in various tissues (5,24,25).
To further investigate if Ca2+ aﬀects [3H]Ins(1,4,5)P3
binding, we studied the eﬀects of various concentrations
of CaCl2 on [3H]Ins(1,4,5)P3 binding to crude platelet
membranes.
cAMP is known to release Ca2+ from permeabilized
platelets. cAMP also phosphorylates Ins(1,4,5)P3 receptors
via cAMP-dependent protein kinase A (PKA) [21]. However,
whether cAMP aﬀects [3H]Ins(1,4,5)P3 binding to platelet
membranes, has not yet been studied. To determine if cAMP
has any eﬀect on Ins(1,4,5)P3 receptors, we investigated the
eﬀect of forskolin, which is known to release endogenous
cAMP, on [3H]Ins(1,4,5)P3 binding to crude platelet mem-
branes.
Findings of the present study suggest that the phar-
macological characteristics of [3H]Ins(1,4,5)P3 binding to
crude platelet membranes are similar to that of Ins(1,4,5)P3
receptors; and that both Ca2+ and cAMP modulate
[3H]Ins(1,4,5)P3 binding in crude platelet membranes. With
these properties, IP3 receptors can be successfully measured
in platelet membranes that can be used to as diagnostic
marker for major mental illnesses, including major depres-
sion, where abnormalities in PI signaling system have been
reported.
2.MaterialsandMethods
2.1. Chemicals. D-myo-[3H]inositol 1,4,5-trisphosphate
(speciﬁc activity 21 Ci/mmol) was obtained from New
England Nuclear (Boston, MA). D-myo-inositol 1,4,5-
trisphosphate, L-myo-inositol 1,4,5-trisphosphate, D-myo-
inositol 2,4,5-trisphosphate, L-α-glycerophosphoinositol
4,5-bisphosphate (GPIP2), heparin sulfate, and forskolin
were purchased from Sigma Chemical Co. (St. Louis, MO).
All other reagents were of analytical grade and were obtained
from Sigma Chemical Co.
2.2. Preparation of Platelet Membranes. Blood (10 to 20mL)
was drawn from healthy normal human subjects into a
tube containing 3.8% (w/v) sodium citrate. The blood was
centrifuged immediately at 210 × gf o r1 0 m i n u t e sa t4 ◦C
to obtain platelet-rich plasma (PRP), which was centrifuged
at 4000 × gf o r1 0m i n u t e sa t4 ◦C. The platelet pellet thus
obtained was homogenized by polytron (at #7 setting) for
30 seconds in a homogenizing buﬀer containing 50mM
Tris-HCl, pH 7.7; 1mM ethylene diamine N
 ,N
 ,N
 ,N
 -
tetraacetic acid (EDTA); and 2mM 2-mercaptoethanol. The
homogenate was centrifuged at 40,000 × gf o r1 5 m i n u t e s
at 4◦C. The supernatant was discarded and the pellet was
homogenized once again in the homogenizing buﬀer and
centrifuged as described above. The resulting pellet was
resuspended in a buﬀer containing 50mM Tris-HCl, pH 8.5;
1mM EDTA; and 1mM 2-mercaptoethanol. This fraction
was used for the [3H]Ins(1,4,5)P3 binding assay. To examine
the eﬀect of CaCl2, the binding assay was performed in
presence or absence of EDTA, as described below.
2.3. [3H]Ins(1,4,5)P3 Binding Assay. The binding of
[3H]Ins(1,4,5)P3 to crude human platelet membranes was
carried out in duplicate. The incubation medium contained
incubation buﬀer (50mM Tris-HCl, pH 8.5; 1mM 2-
mercaptoethanol; 1 mM EDTA), [3H]Ins(1,4,5)P3 (speciﬁc
activity 21Ci/mmol) ranging from 10 to 100nM (six
diﬀerent concentrations), and 40μL of platelet membrane
suspension in a total volume of 100μL. Nonspeciﬁc binding
was determined in the presence of 10μM Ins(1,4,5)P3.
The incubation was performed at 4◦Cf o r1 0 m i n u t e sa n d
rapidly terminated by the addition of 5mL of cold buﬀer
(50mM Tris-HCl, pH 7.7; 1mM EDTA; and 0.1% (w/v)
bovine serum albumin) and ﬁltration through Whatman
GF/B ﬁlters. The ﬁlter-bound radioactivity was analyzed by
a liquid scintillation counter. Speciﬁc binding was deﬁnedCardiovascular Psychiatry and Neurology 3
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Figure 2: Time course of [3H]Ins(1,4,5)P3 binding to human
platelet membranes. Platelet membranes (100μg/protein) were
incubated at 4◦Cf o rd i ﬀerent time intervals in the presence of
20nM [3H]Ins(1,4,5)P3. Nonspeciﬁc binding was estimated in the
presence of 10μM D-Ins(1,4,5)P3. The incubations were rapidly
terminatedbyvacuumﬁltrationatdiﬀerenttimepointsasshownin
theﬁgure.Asinglerepresentativeexperimentisshownforduplicate
determinations.
as the diﬀerence between the total binding and the binding
observed in the presence of D-Ins(1,4,5)P3. The maximum
numberof binding sites (Bmax)andtheapparentdissociation
constant (Kd) were computed by Scatchard analysis using
the EBDA program [22]. Protein was determined by the
method of Lowry et al. [23]. IC50 (concentration of agents
necessary to inhibit half of the speciﬁc Ins(1,4,5)P3 binding)
values of diﬀerent agents (D-Ins(1,4,5)P3; D-Ins(2,4,5)P3;
L-Ins(1,4,5)P3;G P I P 2; and heparin) for the inhibition of
speciﬁc binding were determined by log probit analysis.
To examine the pH-dependence of [3H]Ins(1,4,5)P3
binding and time course for speciﬁc binding of
[3H]Ins(1,4,5)P3,2 0n Mo f[ 3H]Ins(1,4,5)P3 was used.
2.4. Determination of the Eﬀect of CaCl2 on [3H]Ins(1,4,5)P3
Binding. The eﬀects of CaCl2 were studied in the presence
and in the absence of EDTA. Platelet membranes (100μg
protein) were incubated with CaCl2 (0.5 to 30mM) in a
buﬀer containing 50mM Tris-HCl, pH 8.5; 1mM 2 mercap-
toethanol; and 20mM [3H]Ins(1,4,5)P3. EDTA (1mM) was
added totheincubation medium inwhichtheeﬀectofCaCl2
was studied in the presence of EDTA. The incubation was
carried out at 4◦Cf o r1 0m i n u t e s .
2.5. Determination of the Eﬀect of Forskolin on [3H]Ins(1,4,
5)P3 Binding. Platelet protein samples (100μg) were incu-
bated with forskolin (10
−4 to 10
−6 M) in a buﬀer containing
50mM Tris-HCl, pH 8.5; 1mM EDTA; and 1mM 2-
mercaptoethanol. The incubation was carried out at 4◦Cf o r
10 minutes.
3. Results
3.1. pH-Dependence of [3H]Ins(1,4,5)P3 Binding to Platelet
Membranes. The results presented in Figure 1 show that
[3H]Ins(1,4,5)P3 binding to crude platelet membranes
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Figure 3: Saturation isotherm of [3H]Ins(1,4,5)P3 binding to
human platelet membranes. Each point is the mean of duplicate
determination. Binding assays were carried out as described in
Section 2. Nonspeciﬁc binding was determined in the presence of
10μMD-Ins(1,4,5)P3.AScatchardplotof[3H]Ins(1,4,5)P3 binding
is shown in the inset. B = [3H]Ins(1,4,5)P3 speciﬁcally-bound
(fmol/mg protein), B/F = the ratio of speciﬁcally-bound to free
ligand in fmol of Ins(1,4,5)P3 (fmol/mg protein × nM). For this
particular experiment, binding indices are Bmax = 427.56fmol/mg
protein Kd = 21.73nM; and the correlation coeﬃcient (r) = 0.98.
is pH dependent. We measured speciﬁc binding of
[3H]Ins(1,4,5)P3 between pH 4 and 10. Speciﬁc binding
of [3H]Ins(1,4,5)P3 was relatively low at acidic pH (pH
4.0 to 6.0), and increased by 60% as the pH approached
7.0. Speciﬁc binding was stable from pH 7.0 to 8.0, but
it increased further between pH 8.0 to 8.5, and thereafter
declined.
3.2. Time Course for Speciﬁc Binding of [3H]Ins(1,4,5)P3
to Platelet Membranes. We determined the time course for
[3H]Ins(1,4,5)P3 binding to crude platelet membranes from
15seconds up to 60minutes. As shown in Figure 2, the
binding of [3H]Ins(1,4,5)P3 to Ins(1,4,5)P3 receptors was
very rapid. At 15seconds the speciﬁc binding was very low
but it reached equilibrium within 5minutes. After that,
speciﬁc binding remained constant up to 60minutes.
3.3. Saturation Isotherm of [3H]Ins(1,4,5)P3 Binding to
Platelet Membranes. The maximum number of binding sites
(Bmax) and the apparent dissociation constant (Kd)i nc r u d e
platelet membranes were determined by using diﬀerent
concentrations of [3H]Ins(1,4,5)P3. Nonspeciﬁc binding
was determined in the presence of 10μM D-Ins(1,4,5)P3.
Initially, we performed the experiments using 0.1 to 100 nM
[3H]Ins(1,4,5)P3. We observed that at lower concentrations
of [3H]Ins(1,4,5)P3 (0.1 to 10nM), the displacement was too
low to draw the Scatchard plot. A concentration range of
10 to 100nM [3H]Ins(1,4,5)P3, however, showed a speciﬁc
binding of 80% to 50% depending upon the concentration4 Cardiovascular Psychiatry and Neurology
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Figure 4:Displacementcurvefortheinhibitionof[3H]Ins(1,4,5)P3
binding to human platelet membranes by inositol phosphates.
Platelet membranes were incubated with 20nM [3H]Ins(1,4,5)P3
in the presence of increasing concentrations of D-Ins(1,4,5)P3 (),
D-Ins(2,4,5)P3 (•), GPIP2 (), and L-Ins(1,4,5)P3 ()a t4 ◦Cf o r
10minutes. The data are the mean ± S.E.M. of three independent
experiments,each runinduplicate. TheIC50values werecalculated
using the displacement curve (Table 1).
of [3H]Ins(1,4,5)P3. Figure 3 represents a typical saturation
isotherm and a Scatchard plot (inset) of [3H]Ins(1,4,5)P3
binding to platelet membranes. Speciﬁc binding is saturable
between80t o100nM[ 3H]Ins(1,4,5)P3.Nonspeciﬁcbinding
is nonsaturable and linear with a concentration of 10 to
100 mM [3H]Ins(1,4,5)P3. The Scatchard plot indicates a
single class of binding site. The means of Bmax and Kd of ﬁve
independentexperimentsperformedinduplicatewerefound
to be 427.77 ± 56.67fmol/mg proteins and 22.09±2.34nM,
respectively.
3.4. Speciﬁcity of [3H]Ins(1,4,5)P3 Binding. The pharmaco-
logical characterization of Ins(1,4,5)P3 receptors was carried
out using diﬀerent agents known to inhibit [3H]Ins(1,4,5)P3
binding. A displacement curve of [3H]Ins(1,4,5)P3 bind-
ing with diﬀerent concentrations of inositol phosphates is
shown in Figure 4. Of the various inositol phosphates, D-
Ins(1,4,5)P3 was found to be the most potent inhibitor of
[3H]Ins(1,4,5)P3 binding, with an IC50 value of 0.3μM.
Next in order were D-Ins(2,4,5)P3 (IC50 = 1.9μM), GPIP2
(IC50 = 4.97μM), and L-Ins(1,4,5)P3 (IC50 = 354μM).
Heparin acts as an antagonist on the Ins(1,4,5)P3 receptor
and inhibited [3H]Ins(1,4,5)P3 binding in a concentration-
dependent manner (5 to 500μg/mL), with an IC50 value of
36.79 ± 6.0lμg/mL (Table 2 and Figure 5).
3.5. Eﬀects of CaCl2 on [3H]Ins(1,4,5)P3 Binding to Platelet
Membranes. Ca2+ has been shown to be a potent modulator
of [3H]Ins(1,4,5)P3 receptors. In the present investigation,
Table 1: Apparent maximum binding sites (Bmax) and dissociation
constants (Kd)o f[ 3H]Ins(1,4,5)P3 binding to human platelet
membranes. Saturation analysis of Ins(1,4,5)P3 binding sites was
carried out using diﬀerent concentrations of [3H]Ins(1,4,5)P3 as
described in Section 2. Nonspeciﬁc binding was determined in the
presence of 10μM D-Ins(1,4,5)P3. Each value is the mean ± S.E.M
for ﬁve independent experiments performed in duplicate.
Bmax Kd
(fmol/mg protein) (nM)
427.77 + 56.67 22.09 + 2.34
Table 2: Displacement of [3H]Ins(1,4,5)P3 binding by inositol
phosphates and heparin in human platelet membranes. Platelet
membranes were prepared as described in Section 2. The assay
medium (100μL) contained 20nM [3H]Ins(1,4,5)P3 with various
concentrations of competitive substances and approximately 100μg
of protein. Incubations were carried out at 4◦Cf o r1 0m i n u t e s .I C 50
values were calculated by using log probit analysis. The values are
the mean ± S.E.M. of three diﬀerent experiments.
Compound IC50
—( μMo r∗μg/mL)
D-Ins(1,4,5)P3 0.3 ± 0.5
D-Ins(2,4,5)P3 1.90 ± 0.68
GPIP3 4.97 ± 1.83
L-Ins(1,4,5)P3 354.0 ± 37.0
Heparin 36.79 ± 6.0l
∗
we determined the eﬀects of CaCl2 on [3H]Ins(1,4,5)P3
binding to crude platelet membranes in the presence and
in the absence of 1mM EDTA. In the presence of EDTA,
CaCl2 inhibited [3H]Ins(1,4,5)P3 binding in a linear fashion
depending upon its concentration. At a lower concentration
(0.5mM) the degree of inhibition was maximum (68%),
while at a higher concentration (15mM) the inhibition was
very low (5%). At concentrations above 15mM, however,
CaCl2 stimulated [3H]Ins(1,4,5)P3 binding, and at 30mM
CaCl2, a four- to ﬁvefold increase in [3H]Ins(1,4,5)P3 bind-
ing was observed (Figure 6). In another set of experiments,
we observed the eﬀects of CaCl2 in the absence of EDTA.
The results, shown in Figure 6(b), demonstrate that CaCl2
increased [3H]Ins(1,4,5)P3 binding to platelet membranes
between 24% to 64% depending on the concentration (2 to
15mM).AtaCaCl2 concentrationof30mM,thestimulation
of[3H]Ins(1,4,5)P3 bindingtocrudeplateletmembraneswas
nearly the same (fourfold)as that observed in the presence of
1mM EDTA.
3.6. Eﬀects of In-Vitro Addition of Forskolin on [3H]Ins(1,4,
5)P3 Binding in Platelet Membranes. Since cAMP has been
shown to inhibit Ca2+ release from permealized platelets,
and there is indirect evidence which shows that cAMP causes
the phosphorylation of Ins(1,4,5)P3 receptors by stimulating
PKA, we studied the eﬀects of forskolin on [3H]Ins(1,4,5)P3
binding to platelet membranes. Forskolin is a potent stim-
ulator of adenylyl cyclase in platelets and thus increases
cAMP levels of hydrolyzing adenosine trisphosphate (ATP).Cardiovascular Psychiatry and Neurology 5
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Figure 5: Inhibition of [3H]Ins(1,4,5)P3 binding to human platelet
membranes by heparin. Experimental conditions are similar to
thosedescribedinFigure 4.Thepointsrepresentthemean ±S.E.M.
of three independent experiments, each run in duplicate.
We added diﬀerent concentrations of forskolin in vitro, and
the results, given in Figure 7, show that forskolin inhib-
ited [3H]Ins(1,4,5)P3 binding in a concentration-dependent
manner. At a concentration of 10
−4 M, inhibition was about
80%, whereas at lower concentrations (10
−5 to 10
−6 M),
forskolin inhibited Ins(1,4,5)P3 binding by 20% to 30%.
4. Discussion
The pharmacological properties of Ins(1,4,5)P3 receptors
have been characterized in several tissues including the brain
[5, 8]. In an earlier study, Varney et al. [24]o b s e r v e da
single [3H]Ins(1,4,5)P3 binding site in crude platelet mem-
branes; however, they did not fully characterize Ins(1,4,5)P3
receptors in this fraction of platelets. To investigate if
Ins(1,4,5)P3 receptors in crude platelet membranes possess
similar pharmacological properties as observed in other
tissues, we characterized [3H]Ins(1,4,5)P3 binding sites in
crude platelet membranes obtained from normal human
control subjects. We observed a single, saturable binding
site of [3H]Ins(1,4,5)P3 in crude platelet membranes, with
a binding capacity of 427.77fmol/mg protein and an aﬃnity
of 22.09nM. The binding of [3H]Ins(1,4,5)P3 was pH- and
time dependent. The optimum pH was found to be 8.5,
with a steep change occurring in the pH range of 4 to 9.
Time-course experiments revealed that maximum binding
occurred at 2 minutes and remained stable up to 60minutes.
We determined IC50 values of diﬀerent inositol phosphates
in crude platelets membranes. D-Ins(1,4,5)P3 was found to
be the most potent, with an IC50 value of 0.3μM. Heparin
is a competitive antagonist of the Ins(1,4,5)P3 receptor [5].
In the present study, heparin inhibited [3H]Ins(1,4,5)P3
binding in a concentration-dependent manner, with an IC50
value of 36.79 μg/mL. These pharmacological properties of
Ins(1,4,5)P3 receptors in crude platelet membranes were
found to be similar to those reported in other tissues [5, 8].
Earlier,Hwang[20]characterized[3H]Ins(1,4,5)P3 receptors
in puriﬁed human platelet membranes rich in dense tubular
systems. In this fraction of platelet membranes, Hwang
reported two binding sites of [3H]Ins(1,4,5)P3,o n ew i t h
low aﬃnity, and another with high aﬃnity; however in our
study, we observed only one binding site in crude platelet
membranes, which is very similar to that reported by Varney
et al. [24]. One binding site has also been reported in other
tissues [6, 10, 25]. It is quite possible that the explanation
of the single binding site observed by us and Varney et
al. in crude platelet membranes and the two binding sites
observed by Hwang in puriﬁed platelet membranes may be
thediﬀerencesinthepreparationofplateletmembranes.The
pH- and the time-course proﬁles observed in the present
study are similar to those reported in other tissues, including
platelets [5, 7, 9, 20].
In continuation of our study, we further investigated the
eﬀects of agents that are known to modulate Ins(1,4,5)P3
receptors. One such agent is Ca2+, which has been shown
to aﬀect [3H]Ins(1,4,5)P3 binding in most tissues [5, 25,
26]. In the present investigation, we studied the eﬀects of
variousconcentrationsofCaCl2 on[3H]Ins(1,4,5)P3 binding
to crude platelet membranes. Since EDTA is known to
chelate Ca2+ and our incubation medium contained 1mM
EDTA, we studied the eﬀects of CaCl2 in the presence and
in the absence of EDTA. We observed that CaCl2 stimu-
lated[3H]Ins(1,4,5)P3 bindinginaconcentration-dependent
manner (2 to 15mM), and at a concentration of 30mM,
the stimulation was four- to ﬁvefold. In the presence of
EDTA, however, CaCl2 inhibited [3H]Ins(1,4,5)P3 binding.
We observed maximum inhibition at 0.5mM, and the
degree of inhibition decreased as the concentration of CaCl2
increased (0.5 to 15mM); and at a concentration of 30mM,
CaCl2 stimulated [3H]Ins(1,4,5)P3 binding, the degree of
stimulation being similar to that observed in the absence of
EDTA. These results suggest a biphasic response of CaCl2 on
[3H]Ins(1,4,5)P3 binding to platelet membranes.
The mechanism by which Ca2+ inhibits [3H]Ins(1,4,5)P3
binding in platelets is presently unclear. Delfert et al. [27]
reported an inhibitory eﬀect in the release of Ca2+ from
the endoplasmic reticulum in the presence of free Ca2+.I t
is possible that Ca2+ itself regulates the further release of
Ca2+ by inhibiting Ins(1,4,5)P3 binding. Danoﬀ et al. [28]
hypothesized that the inhibitory eﬀect of Ca2+ is mediated
by a protein called calmedin in the cerebral membranes
of rats; while Mignery et al. [29] suggested that Ca2+-
inducedinhibitionismediatedbyCa2+-activatedPLC,which
produces additional Ins(1,4,5)P3, with an apparent decrease
in [3H]Ins(1,4,5)P3 binding. Whether this mechanism exists
in platelets is not known at the present time.
Our studies also indicate that EDTA markedly alters
the eﬀect of CaCl2 on [3H]Ins(1,4,5)P3 binding. There
is a possibility that 1mM EDTA chelated most of the
Ca2+, leaving a micromolar concentration of Ca2+,w h i c h
was able to inhibit [3H]Ins(1,4,5)P3 binding, since it has
been shown that inhibition of [3H]Ins(1,4,5)P3 binding
occurs at micromolar concentrations of Ca2+ [30]. However,
when we increased the concentration of CaCl2 to 30 mM,
there was not enough EDTA present in the medium to
chelate Ca2+, and the concentration of Ca2+ present in the
medium was high enough to stimulate [3H]Ins(1,4,5)P36 Cardiovascular Psychiatry and Neurology
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Figure 6: Eﬀects of CaCl2 on [3H]Ins(1,4,5)P3 binding to human platelet membranes in the presence (a) and absence (b) of EDTA. Platelet
membranes were incubated with increasing concentrations of CaCl2 in the presence of 20nM [3H]Ins(1,4,5)P3 in a buﬀer containing 50mM
Tris-HCl, pH 8.4; 1mM EDTA; and 1mM 2-mercaptoethanol at 4◦C for 10minutes. The data represent the inhibition or stimulation of
[3H]Ins(1,4,5)P3 binding to platelet membranes. The points represent the mean ± S.E.M. of three independent experiments, each run in
duplicate.
binding. In the absence of EDTA, however, CaCl2 stimulated
[3H]Ins(1,4,5)P3 binding. The mechanism by which CaCl2
potentiated the binding is not known at this present time
andneedsfurtherstudy.Nonetheless,thisstudysuggeststhat
CaCl2 modulates [3H]Ins(1,4,5)P3 binding in platelets.
Another important modulator in Ins(1,4,5)P3 receptors
is cAMP, which has been shown to release Ca2+ from
platelet membranes and is involved in phosphorylation of
[3H]Ins(1,4,5)P3 receptors [31, 32]. To investigate the eﬀects
of cAMP on [3H]Ins(1,4,5)P3 binding, we added forskolin
in vitro to the assay medium. Forskolin is known to act
directly on adenylyl cyclase, thereby generating endogenous
cAMP. We found that forskolin inhibited [3H]Ins(1,4,5)P3
binding in platelets in a concentration-dependent manner.
The mechanism by which cAMP inhibits [3H]Ins(1,4,5)P3
binding is not clear at this present time. It is quite possible
that the inhibition observed in [3H]Ins(1,4,5)P3 binding to
platelet membranes by forskolin might be due to the phos-
phorylation of Ins(1,4,5)P3 receptors by cAMP-dependent
PKA [31, 32]. The possibility that forskolin acts directly on
[3H]Ins(1,4,5)P3 binding cannot be ruled out, however.
In summary, our study shows a single, saturable binding
site for [3H]Ins(1,4,5)P3 in crude platelet membranes,
which is time dependent and modulated by pH, inositol
phosphates, heparin, Ca2+, and cAMP. Although there is
a minor diﬀerence between the results obtained in crude
platelet membranes in this study as compared to the
results in puriﬁed platelet membranes, the pharmacological
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Figure 7: Inhibitory eﬀect of forskolin on [3H]Ins(1,4,5)P3
binding to human platelet membranes. The experiments were
performed in an assay medium (50mM Tris HC1, pH 8.4; 1mM
EDTA; 1mM 2-mercaptoethanol) containing 30mM CaCl2 20nM
[3H]Ins(1,4,5)P3, and increasing concentrations of forskolin at
4◦C for 10minutes. The data are the mean ± S.E.M. of three
independent experiments, each carried out in duplicate.Cardiovascular Psychiatry and Neurology 7
characteristics of [3H]Ins(1,4,5)P3 binding to crude platelet
membranes are similar to the pharmacological properties of
Ins(1,4,5)P3 receptors in other tissues, including platelets.
These results are important, especially considering that due
to the diﬃculty of obtaining large-enough samples of blood
from patients, preparation of puriﬁed platelet membranes
is not feasible for clinical research. Since the preparation
of crude platelet membranes is convenient and requires a
smaller amount of blood, this procedure can be utilized to
study the role of Ins(1,4,5)P3 receptors in depression and
other mental disorders, such as schizophrenia or bipolar
disorders. Even, within a speciﬁc diagnosis, measuring IP3
receptors may be helpful in distinguishing subtypes of
mental illness. For example, it will be interesting to examine
whether IP3 receptors are altered in a subset of depressed
patients. In this regard, the prime example is protein kinase
A, which has been shown to be altered in a subtype of
depressed patients, that is, melancholic depressed patients or
patients who committed suicide [33, 34]. Thus, measuring
IP3 receptors in blood cells may lead to the development
of novel interventions that could target speciﬁc points of
vulnerability.
Abbreviations
Bmax Maximum number of binding sites
cAMP Cyclic adenosine monophosphate
EDTA Ethylene diamine N , N , N ,
N -tetraacetic acid
GPIP2 L-α-glycerophosphoinositol
4,5-bisphosphate
Kd Apparent dissociation constant
Ins(1,4,5)P3 Inositol (1,4,5) triphosphate
PKA Protein kinase A
PI Phosphatidylinositol
PKC Protein kinase C
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